Endpoint | HPV vaccine cases (n = 9342) | Placebo cases (n = 9400) | % Efficacy | 95% CI |
---|---|---|---|---|
(http://www.cdc.gov/nip/acip/slides/jun06/hpv-2-barr.pdf) | ||||
HPV-negative modified intention to treat (HN-MITT): endpoint HPV16/18-related CIN3 and/or AIS | ||||
AIS, ; CIN, cervical intra-epithelial neoplasia; HPV, human papillomavirus. | ||||
HPV16/18-related CIN3 or AIS | 0 | 52 | 100 | 93,100 |
HPV16/18-related CIN3 | 0 | 47 | 100 | 92,100 |
HPV16/18-related AIS | 0 | 9 | 100 | 49,100 |